Searched for
BLOCKBUSTER CANCER DRUG
India's weight-loss drug boom raises questions over healthcare prioritiesIndia's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes, concerns abou...- AbbVie loses patent plea for Hep C drugThe Indian Patent Office has denied a secondary patent for AbbVie's Hepatitis C drug Maviret. This decision ensures continued access to aff...
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garageKiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...
- Merck nears $10 bn deal for respiratory drugmaker Verona: ReportsMerck is close to buying Verona Pharma, a biotech firm specializing in lung diseases. The deal is valued at around $10 billion. Merck aims ...
- Dr Reddy’s, Alvotech to co-develop Keytruda biosimilarDr. Reddy's Laboratories and Alvotech are collaborating to develop, manufacture, and commercialize a biosimilar version of Keytruda, a high...
- India's pharma, meditech exports expected to sustain momentum despite global slowdown: OfficialIndia's pharmaceutical and meditech exports continue to grow despite global economic slowdown, with robust double-digit growth. Government-...
- AstraZeneca targets 2024 growth but mixed views hit sharesIn almost a decade since AstraZeneca fended off a takeover by U.S. rival Pfizer, CEO Pascal Soriot has rebuilt the Anglo-Swedish drugmaker'...
- Bristol Myers to buy Mirati for $4.8 billionThe purchase will give a boost to Bristol as patent expirations weigh on sales of its oncology medicines. The company had to slash its reve...
- Biocon surges 14% on USFDA approval to biosimilar drugWith annual sales of $3.16 billion globally, Trastuzumab is expected to touch nearly $10 billion by 2020.
- Intas launches biosimilar Bevacizumab with aggressive pricingBiosimilar drugs are the follow on versions of biologic drugs which are composed of sugars, proteins, nucleic acids or complex combinations...
- MSD launches blockbuster cancer drug Keytruda in IndiaDCGI gave MSD permission to market Keytruda in June 2016, according to minutes of the regulator’s Subject Expert Committee on oncology and ...
- Breakthrough cancer drugs all set for India launchThe accelerated regulatory clearances cut the time lines for introductions of the two big brands which may be expected to be introduced by ...
- Roche’s reputation at stake if Avastin biosimilar approved without trial: Kapil SibalThe judge asked the company to submit a compilation of judgments highlighting the protection given to drug innovators to support its call.
- Dr Reddy's plunges nearly 2% on patent infringement suitDr Reddy's Laboratories plunged as much as 1.85% in a weak market on Monday after Genzyme Corporation filed a suit against the company.
- Genzyme Corporation files patent infringement suit against DRLMozobil (plerixafor injection) is a hematopoietic stem cell mobiliser indicated to patients with non-Hodgkin's lymphoma (blood cancer) and ...
- Doctors call for reduction in cancer drug pricesAdvocating for lower drug prices is a necessity to save the lives of patients who cannot afford them,” said a research report backed by the...
- Novartis condemns Supreme Court's patent bid for cancer drugNovartis condemned the Supreme Court's dismissal of its patent bid for a blockbuster cancer drug, saying it "discourages future innovation".
- Novartis buys part of generics maker for $1.2 bnSwiss pharmaceuticals giant Novartis AG will buy the generic injectable cancer drugs business of Austria's EBEWE Pharma for euro925 million...
- Roche files for Avastin to treat breast cancer in EuropeSwiss drugmaker Roche has filed its Avastin drug for use in previously untreated advanced breast cancer in Europe, the company said on Mond...
Load More
